View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 19, 2016updated 18 Jul 2018 10:22am

How to Fundraise if you’re a Start-up

CTA explains some of the best ways to fundraise if you’re a small start-up

By Staff Writer

Picture this scenario: You’re a small start-up, about to embark on your first trial and your team has been hauled up in a conference room all day brainstorming ways to raise money. If that describes your company, this is probably not an uncommon scenario. Raising funds in an arguably cash depleted industry is no mean feat at the best of times.

Free Whitepaper
img

Enabling Access to Medicines: What Manufacturers and Patients Need to Know

Early Access Programs (EAPs) are a pathway for pharmaceutical companies to provide innovative drugs to patients living with serious conditions. These treatments may still be in development or already have approval somewhere in the world. This white paper provides an overview of the key information drug developers and patients need to know about access programs and touches on the role Tanner Pharma Group plays in enabling global access to critical medicines.
by Tanner Pharma Group
Enter your details here to receive your free Whitepaper.

However, over the years, start-ups have been able to secure major deals from venture capitals proving small companies can more than punch above their weight. Examples include medical device companies, Tryton Medical and GlySure which in 2013 each secured deals worth $24million and $13.6million respectively for their medical device trials. When taking a closer look at the reasons behind their successes, experts pointed to the fact that both companies were able to demonstrate not only solid clinical data, but the economic value of their investigational product.

So if you’re a small company embarking on your first trial, what are the core tenets to successful fundraising? CTA provides three tips to consider:

Acknowledge the Pitfalls

When attempting to get investors onboard, a large part of the challenge comes in getting them to buy in to your product. Despite all the positive data you may have gathered in the preclinical stage, animal data does not equate to human data. What’s more, with long timelines a given, the high risk nature of clinical trials is often a deterrent for prospective investors, so acknowledging that is key. Therefore, sponsors must be able to convince stakeholders of the financial merits of the product you are trying to develop. In a recent interview with CTA, Jan Mous, CEO, Pharmida identified immuno-oncology as the field with the most promise. With new drugs in this field showing vast improvements in the treatment of certain cancers, Mous says there are numerous benefits for both researchers and investors. Furthermore, he advised if your drug (or device) can demonstrate you have something innovative to offer (along with positive preclinical results), the chances of garnering support from investors are high.

How to Launch

For small businesses of any kind, getting off the ground can often be the largest stumbling block. Raising funds for a start-up is a three stage process. The initial stage, which experts call the ‘friends and family’ round is where you receive preliminary funding to help setup your company. What is critical at this stage is to have a well thought out budget that lays out to your investors what exactly they are buying into. Additionally, companies must map out to early stakeholders how they intend to secure financing in the following rounds of investment. The next two rounds involve investments from bigger players, such as venture groups and large pharma companies that find the first stage too dangerous to invest. Once all the necessary funds are secured, you should be ready to move ahead with regulatory submissions and so forth.

Demonstrate clear reporting

This is where it’s important to understand who your users will be. Validate your product to investors by demonstrating clear and exceptional reporting. Remember, the earlier you can show human data, the better as investors will be looking to glean whether phase 1 will be successful. Also, show that you have thorough contingency plans in place in the event things go wrong. When it comes to pitching investors, saying you have the best investigational product is not enough. You have to show stakeholders (patients, doctors, hospitals and financial backers) that there’s a huge impact potential for your drug or device.

 

 

References

Robin Mansukhani, CEO, Alzeca Biosciences, ‘A Start-up Perspective on Fundraising’ (Presentation)Damian Garde, ‘JPM: For med tech startups, fundraising hinges on proving value’ – http://bit.ly/1MFWy9sIain Sanderson, ‘Medical Device Start-Ups and the funding challenge’ – http://www.iansandison.co.uk/blog.phpWilliam Stewart, Jeanette Stewart, and Lindsay Nelson, ‘First Steps in Creating a Pharma Start-up’ – http://bit.ly/1MFWM0i

Free Whitepaper
img

Enabling Access to Medicines: What Manufacturers and Patients Need to Know

Early Access Programs (EAPs) are a pathway for pharmaceutical companies to provide innovative drugs to patients living with serious conditions. These treatments may still be in development or already have approval somewhere in the world. This white paper provides an overview of the key information drug developers and patients need to know about access programs and touches on the role Tanner Pharma Group plays in enabling global access to critical medicines.
by Tanner Pharma Group
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena